See you next year!

Nov 29, 2016

Parametric maps obtained with SRTM2 (cerebellum grey matter as reference) for the group of healthy participants (top) and from one representative participant with suspected CTE (bottom). CTE: chronic traumatic encephalopathy.

SNMMI: PET tracer detects CTE tau pathology in living patients

May 31, 2026

Sample images from each participant group: A: CT only; B: fused Tc-99m maraciclatide SPECT/CT.

SNMMI: SPECT/CT tracer shows promise in interstitial lung disease

May 31, 2026

SNMMI: Alpha-emitting tracer offers neuroendocrine tumor treatment option

May 31, 2026

ASCO: Should pathogenic variants be considered in breast cancer screening?

May 31, 2026

SNMMI: PET tracer detects CTE tau pathology in living patients

By Kate Madden Yee

Study findings suggest "a clinical role for PET in traumatic brain injury and sports- and military-related neurodegeneration."

May 31, 2026

Parametric maps obtained with SRTM2 (cerebellum grey matter as reference) for the group of healthy participants (top) and from one representative participant with suspected CTE (bottom). CTE: chronic traumatic encephalopathy.

SNMMI: SPECT/CT tracer shows promise in interstitial lung disease

Differentiating between fibrotic scarring and inflammation stages of disease is critical so that physicians can determine what treatment is best for the patient.

May 31, 2026

Sample images from each participant group: A: CT only; B: fused Tc-99m maraciclatide SPECT/CT.

SNMMI: Alpha-emitting tracer offers neuroendocrine tumor treatment option

By Kate Madden Yee

An alpha-emitting radiotracer produced remission in patients who had exhausted typical treatment options for neuroendocrine tumors.

May 31, 2026

ASCO: Should pathogenic variants be considered in breast cancer screening?

By Erik L. Ridley

Germline testing for PVs identify different subsets of high-risk women in risk-based breast cancer screening strategies.

May 31, 2026

SNMMI: PET tracer detects both cardiac Inflammation and tumor activity

CCR2 is expressed in both atherosclerotic plaques and tumors.

May 31, 2026

Combination therapy of JAK1i with anti-PD1 slows down tumor growth and reduces CCR2+ cells infiltration in atherosclerotic lesions compared to anti-PD1 alone. Representative PET images of cardio-oncology mice treated with anti-PD1 alone or in combination with JAK1i. The PET uptake was normalized by subtracting blood retention.

SNMMI: Prostate cancer vaccines may improve response to Pluvicto

Immunological priming before radiopharmaceutical therapy may enhance clinical efficacy without impairing prostate antigen-specific T cell response.

May 31, 2026

ASCO: Lu-177 edotreotide yields sustained quality-of-life gains

By Erik L. Ridley

A poster presentation at ASCO 2026 highlighted quantifiable benefits for patients receiving the radiopharmaceutical treatment for GEP-NETs.

May 31, 2026

SNMMI: Jeremie Calais discusses theranostics (and football)

Jeremie Calais, MD, of the University of California, Los Angeles, discussed the present state of the field of theranostics, as well as it’s future potential.

May 31, 2026

SNMMI: Phillip Kuo discusses Alzheimer’s disease imaging and treatment

Phillip Kuo, MD, PhD, discussed developments in diagnosing and treating Alzheimer’s disease at the SNMMI meeting.

May 31, 2026

SNMMI: Music relieves anxiety, cuts perceived SPECT/CT scan time

By Kate Madden Yee

Research findings could improve the experience of patients undergoing these exams as well as the quality of the imaging itself.

May 31, 2026

SNMMI: New brain imaging agent tracks progressive supranuclear palsy

By Kate Madden Yee

The tracer, called [F-18] OXD-2314, successfully identified abnormal proteins in key brain regions of patients with the disease.

May 31, 2026

SNMMI: Machine-learning model predicts RPT dose

Dosimetry plays a central role in optimizing lutetium-177 (Lu-177) PSMA therapy, yet calculating it currently depends on post-therapy imaging.

May 30, 2026

Page 1 of 229